Trials / Recruiting
RecruitingNCT05003960
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Autism
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Autism
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- Sponsor
- The Foundation for Orthopaedics and Regenerative Medicine · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Autism
Detailed description
Studies have shown that stem cell treatment is safe and efficacious for the treatment of Autism. Patients with Autism will receive a single intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells. The total dose for the infusion will be 100 million cells. Patients will be evaluated within one month pre treatment and at 1, 6, 12, 24, 36, and 48 months post treatment for safety and efficacy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | AlloRx | cultured allogeneic adult umbilical cord derived mesenchymal stem cells |
Timeline
- Start date
- 2022-01-23
- Primary completion
- 2027-12-01
- Completion
- 2027-12-01
- First posted
- 2021-08-13
- Last updated
- 2025-04-08
Locations
3 sites across 2 countries: Antigua and Barbuda, Greece
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05003960. Inclusion in this directory is not an endorsement.